IMIC(000516) Zhong Guo Xin Wen Wang·2025-05-16 11:03Core Viewpoint - The Guangxi Zhuang Autonomous Region's Finance Department has significantly increased financial support for the Fangchenggang International Medical Open Experimental Zone, raising a total of 41.22 billion RMB since 2019 to enhance infrastructure and promote high-quality industrial development in the region [1][2] Group 1: Financial Support and Infrastructure Development - The Finance Department has allocated a total of 25.37 billion RMB to support various projects, including the construction of infrastructure for the non-human primate conservation base [1] - The financial support has effectively promoted the construction of infrastructure and improved the comprehensive carrying capacity of the experimental zone, facilitating the accelerated gathering of three main industries: breeding of experimental animals, preclinical drug research, and traditional medicine development [1] - As of April 2025, the experimental zone has registered 264 enterprises, including 23 high-tech enterprises and 50 recognized technology-based small and medium-sized enterprises [1] Group 2: Healthcare and Medical Services - The Finance Department has also allocated 13.55 billion RMB to support major healthcare projects, including the construction of a major epidemic treatment base and the relocation of the disease prevention and control center in Fangchenggang [1] - The collaboration between Guangxi People's Hospital and Fangchenggang First People's Hospital aims to establish the first regional medical center in the autonomous region, focusing on six key specialties, including cardiology [2] - The number of hospital beds per thousand people in Fangchenggang has increased from 4.23 in 2019 to 5.42 in 2024, indicating an expansion of quality medical resources [2] Group 3: Research and Innovation - A total of 2.3 billion RMB has been allocated to support the construction of a food safety and nutrition innovation platform and various research projects related to non-human primates, medical service models, drug treatment, and smart medicine [2] - The experimental zone has achieved breakthroughs in innovation and research, including the creation of the world's first non-alcoholic fatty liver disease model using non-human primates [2] - The Guangxi Luhang Biopharmaceutical Technology Co., Ltd. has received clinical approval for its targeted drugs AHT-101 and AHT-102 for gastric and pancreatic cancer [2]